United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read General business news SThree plc (LSE: STEM) posts FY25 profit decline but launches £20m buyback amid cautious recovery signs SThree posts FY25 earnings with a 62% profit drop but launches £20M buyback and eyes FY26 recovery. Find out how the company is repositioning today. byVenkateshJanuary 27, 2026